Idera Pharmaceuticals Announces Tilsotolimod Updates
14 déc. 2021 16h32 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its...
Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
29 avr. 2021 16h10 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended...
Idera Pharmaceuticals to Present at Upcoming Conferences
11 janv. 2021 06h02 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences. “2021 represents a...
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
15 déc. 2020 08h05 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
17 nov. 2020 16h27 HE
|
Idera Pharmaceuticals, Inc.
– COO Role is Key to Preparedness for NDA Filing and Commercial Launch –– Clayton Fletcher, Head of Business Development & Strategic Planning, to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE...
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
29 oct. 2020 16h36 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
28 sept. 2020 08h45 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
04 août 2020 16h10 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
15 juil. 2020 08h05 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
02 juin 2020 08h15 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...